Every 10-Q that FibroBiologics, Inc. (FBLG) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow FBLG and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FBLG filings page.
FibroBiologics, Inc. is a clinical-stage cell-therapy company developing fibroblast-based treatments for chronic diseases. For the three and six months ended June 30, 2026, it reported net losses of $4,117 thousand and $9,117 thousand, driven by research and development expenses of $1,658 thousand and $4,611 thousand and general, administrative and other expenses of $2,375 thousand and $4,490 thousand, respectively.
Cash and cash equivalents were $3,515 thousand and total assets $7,929 thousand as of June 30, 2026, with net cash used in operating activities of $7,655 thousand in the first half. The company raised capital through a March SEPA draw, an April registered offering (including common stock and pre-funded warrants), an at-the-market program, and a June private placement of $3,000 thousand of pre-funded warrants plus accompanying warrants, contributing to additional paid-in capital of $67,916 thousand. Management states that its cash balance, continued losses and lack of revenue raise substantial doubt about its ability to continue as a going concern.
The pipeline advanced with a Phase 1/2 diabetic foot ulcer trial of CYWC628 in Australia, though enrollment is slower than planned; interim six-week data are expected after a defined number of patients per arm complete treatment. The company also discloses a Nasdaq Staff Determination to delist its securities for bid-price noncompliance and has requested a hearing, which temporarily stays delisting while it seeks to regain compliance.
FibroBiologics, Inc. (FBLG) reported another quarterly loss as it funds multiple fibroblast-based cell therapy programs. For the three months ended March 31, 2026, the company recorded a net loss of $5.0 million, similar to the prior year period, as operating expenses rose to $5.1 million. Research and development spending increased to $3.0 million, reflecting preparation for clinical trials, while general and administrative costs declined to $2.1 million.
Cash and cash equivalents fell to $1.5 million as of March 31, 2026, from $4.9 million at year-end, and management disclosed “substantial doubt” about the company’s ability to continue as a going concern without additional capital. To help fund operations, FibroBiologics used its standby equity purchase agreement to sell 133,108 shares for about $0.7 million in March and later completed an April registered offering that raised approximately $2.5 million net.
The company executed a 1-for-20 reverse stock split on March 30, 2026, leaving 5,208,915 common shares outstanding as of April 30, 2026. FibroBiologics continues to advance several programs, including CYWC628 for diabetic foot ulcers, CYPS317 for psoriasis, CYMS101 for multiple sclerosis, and CybroCell™ for degenerative disc disease, but it has not yet generated revenue. Management also reported a material weakness in internal control over financial reporting related to segregation of duties and plans to add accounting staff and strengthen controls.
FibroBiologics (FBLG) filed its Q3 2025 report showing higher expenses and a wider loss, alongside a going concern warning. For the quarter ended September 30, 2025, operating expenses rose to $5.0 million, driven by research and development of $2.8 million and general and administrative of $2.2 million. The company reported a net loss of $5.8 million for the quarter and $15.4 million for the nine months.
Cash and cash equivalents were $4.9 million, down from $14.0 million at year-end, with net cash used in operations of $13.2 million year-to-date. Management states that these conditions raise substantial doubt about the company’s ability to continue as a going concern.
The company detailed its Standby Equity Purchase Agreement, under which it issued $15.0 million in short-term convertible notes in three tranches and may require the investor to purchase up to an additional $10.0 million of common stock, subject to conditions. During 2025, $9.7 million of notes converted into 13,059,270 shares; additional conversions occurred in October. Shares outstanding were 48,263,979 as of September 30, 2025, and 51,456,077 as of October 31, 2025.